The Glucagon-Like Peptide 1 Analogue Exendin-4 Attenuates the Nicotine-Induced Locomotor Stimulation, Accumbal Dopamine Release, Conditioned Place Preference as well as the Expression of Locomotor Sensitization in Mice
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
The gastrointestinal peptide glucagon-like peptide 1 (GLP-1) is known to regulate consummatory behavior and is released in response to nutrient ingestion. Analogues of this peptide recently emerged as novel pharmacotherapies for treatment of type II diabetes since they reduce gastric emptying, glucagon secretion as well as enhance glucose-dependent insulin secretion. The findings that GLP-1 targets reward related areas including mesolimbic dopamine areas indicate that the physiological role of GLP-1 extends beyond food intake and glucose homeostasis control to include reward regulation. The present series of experiments was therefore designed to investigate the effects of the GLP-1 receptor agonist, Exendin-4 (Ex4), on established nicotine-induced effects on the mesolimbic dopamine system in mice. Specifically, we show that treatment with Ex4, at a dose with no effect per se, attenuate nicotine-induced locomotor stimulation, accumbal dopamine release as well as the expression of conditioned place preference in mice. In accordance, Ex4 also blocks nicotine-induced expression of locomotor sensitization in mice. Given that development of nicotine addiction largely depends on the effects of nicotine on the mesolimbic dopamine system these findings indicate that the GLP-1 receptor may be a potential target for the development of novel treatment strategies for nicotine cessations in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In AD, GLP-1(7-36) amide inhibits IL-1β transcription and prevents cognitive dysfunction, amyloid precursor protein synthesis, and cell death.”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [425]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It also enhances learning and memory by promoting long-term potentiation (LTP).425,426”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [425]
Experimental — accuracy not yet measuredIn the citing paper
“preclinical studies suggest GLP-1 may also limit nicotine intake, although these effects of GLP-1 appear to be mediated through distinct mechanisms and brain areas.126,127”
From Nicotinic Acetylcholine Receptor Signaling in the Hypothalamus: Mechanisms Related to Nicotine’s Effects on Food Intake (2020) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 13,416
The neural basis of drug craving: An incentive-sensitization theory of addiction
Robinson, T. (1993) · Brain Research Reviews · doi:10.1016/0165-0173(93)90013-p · Cited by 7,346 · cited 2×
“Given that expression of locomotor sensitization has been suggested to reflect the neurochemical alterations underlying important parts of addiction such as craving and compulsive drug taking [29], GLP-1 receptors may have an important role in the development of addiction.”
BackgroundBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 2×
“as the hypothalamus and mesolimbic areas [8-11].”
ResultThe Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 2×
“as the hypothalamus and mesolimbic areas [8-11].”
Resultmouse brain in stereotaxic coordinates
Franklin, K. B. J., & Paxinos, G. (1997) · Cited by 3,258
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“weight [12-14] via GLP-1 receptors expressed in the hypothalamus [15] and the NTS [16].”
BackgroundGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 1×
“weight [12-14] via GLP-1 receptors expressed in the hypothalamus [15] and the NTS [16].”
BackgroundGutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868 · cited 1×
“Clinically available GLP-1 receptor analogues, such as exenatide and liraglutide, are approved for treatment of type II diabetes since they reduce gastric emptying, glucagon secretion as well as enhance glucose-dependent insulin secretion [43-46].”
BackgroundREVIEW: Behavioural assessment of drug reinforcement and addictive features in rodents: an overview
Sanchis‐Segura, C., & Spanagel, R. (2006) · Addiction Biology · doi:10.1111/j.1369-1600.2006.00012.x · Cited by 629 · cited 1×
“Given that development of nicotine addiction partly depends on the effects of nicotine on the mesolimbic dopamine system (for review see [2-4]) and that we here show that Ex4 suppresses established nicotine-induced effects on the mesolimbic dopamine system [26,27,31], we hypothesize that GLP-1 receptors within these r…”
BackgroundDrug addiction: the neurobiology of behaviour gone awry
Volkow, N. D., & Li, T.-K. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1539 · Cited by 625 · cited 1×
“Given that development of nicotine addiction partly depends on the effects of nicotine on the mesolimbic dopamine system (for review see [2-4]) and that we here show that Ex4 suppresses established nicotine-induced effects on the mesolimbic dopamine system [26,27,31], we hypothesize that GLP-1 receptors within these r…”
Long-term administration of d-amphetamine: Progressive augmentation of motor activity and stereotypy
Segal, D. S., & Mandell, A. J. (1974) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(74)90060-4 · Cited by 601
Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats
Tang-Christensen, M., Larsen, P. J., Goke, R., Fink-Jensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r848 · Cited by 597 · cited 1×
“weight [12-14] via GLP-1 receptors expressed in the hypothalamus [15] and the NTS [16].”
BackgroundThorens, B., Porret, A., Bühler, L., Deng, S.-P., Morel, P., & Widmann, C. (1993) · Diabetes · doi:10.2337/diab.42.11.1678 · Cited by 558 · cited 1×
“Exendin-4 has previously been established as a GLP-1 receptor agonist [21] and distribution studies show that the CNS binding of Ex4 is identical to GLP-1 [22].”
BackgroundAlhadeff, A. L., Rupprecht, L. E., & Hayes, M. R. (2012) · Endocrinology · doi:10.1210/en.2011-1443 · Cited by 515 · cited 3×
“Interestingly, GLP-1 neurons in the NTS project directly to the ventral tegmental area as well as the core and shell of nucleus accumbens [17].”
BackgroundThe incretin system and its role in type 2 diabetes mellitus
HOLST, J., VILSBOLL, T., & DEACON, C. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.012 · Cited by 515 · cited 1×
“Clinically available GLP-1 receptor analogues, such as exenatide and liraglutide, are approved for treatment of type II diabetes since they reduce gastric emptying, glucagon secretion as well as enhance glucose-dependent insulin secretion [43-46].”
BackgroundGöke, R., Larsen, P. J., Mikkelsen, J. D., & Sheikh, S. P. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00650.x · Cited by 474 · cited 1×
“Exendin-4 has previously been established as a GLP-1 receptor agonist [21] and distribution studies show that the CNS binding of Ex4 is identical to GLP-1 [22].”
BackgroundDickson, S. L., Shirazi, R. H., Hansson, C., Bergquist, F., Nissbrandt, H., & Skibicka, K. P. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.6326-11.2012 · Cited by 414 · cited 3×
“Even though Ex4 has been suggested to affect other receptors than the GLP-1 receptor [38-40] the findings that a GLP-1 receptor antagonist blocks the ability of Ex4 to reduce the motivation to consume sucrose [32] supports our hypothesis that the reinforcing properties of rewards such as nicotine are mediated directly…”
BackgroundEntry of exendin-4 into brain is rapid but may be limited at high doses
Kastin, A. J., & Akerstrom, V (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802206 · Cited by 355 · cited 1×
“Albeit Ex4 crosses the blood-brain barrier [36] the possibility that the observed effects of Ex4 could be due to peripheral rather than central effects should be considered.”
BackgroundJerlhag, E., Egecioglu, E., Dickson, S. L., Andersson, M., Svensson, L., & Engel, J. A. (2006) · Addiction Biology · doi:10.1111/j.1369-1600.2006.00002.x · Cited by 352
Self-citationArcuate Glucagon-Like Peptide 1 Receptors Regulate Glucose Homeostasis but Not Food Intake
Sandoval, D. A., Bagnol, D., Woods, S. C., D'Alessio, D. A., & Seeley, R. J. (2008) · Diabetes · doi:10.2337/db07-1824 · Cited by 320 · cited 1×
“Glucagon-like peptide 1 receptors found in the hypothalamus and NTS have been shown to regulate GLP-1 dependent food intake [15,16] and glucose homeostasis [35], raising the possibility that GLP-1 receptors in these areas also could be of importance for nicotine-induced activation of the mesolimbic dopamine system and…”
BackgroundRinaman, L. (2010) · Brain Research · doi:10.1016/j.brainres.2010.03.059 · Cited by 311 · cited 1×
“Acc [8,9,17,30].”
Sonne, D. P., Engstrøm, T., & Treiman, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2007.10.001 · Cited by 294
Kanoski, S. E., Rupprecht, L. E., Fortin, S. M., De Jonghe, B. C., & Hayes, M. R. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.12.022 · Cited by 273 · cited 1×
“Albeit previous studies have shown that Ex4, at a dose range similar to what was used in the present study, induces a condition taste aversion [47] the possibility that our results are due to aversion rather than reduced reward appears however less likely.”
ResultRüttimann, E. B., Arnold, M., Hillebrand, J. J., Geary, N., & Langhans, W. (2009) · Endocrinology · doi:10.1210/en.2008-1221 · Cited by 258 · cited 1×
“In accordance, the ability of GLP-1 to reduce spontaneous meal size is dependent on vagal afferent signaling [37].”
BackgroundGlucagon-Like Peptide 1 Receptors in Nucleus Accumbens Affect Food Intake
Dossat, A. M., Lilly, N., Kay, K., & Williams, D. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3262-11.2011 · Cited by 256 · cited 1×
“reduces reward induced by and the intake of palatable foods [17,32] and accumbal administration of GLP-1 receptor antagonists cause hyperphagia, [33].”
BackgroundHayes, M. R., Bradley, L., & Grill, H. J. (2009) · Endocrinology · doi:10.1210/en.2008-1479 · Cited by 228
Neurochemical and behavioral studies on ethanol and nicotine interactions
Larsson, A., & Engel, J. A. (2004) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2003.11.010 · Cited by 220 · cited 1×
“Given that development of nicotine addiction partly depends on the effects of nicotine on the mesolimbic dopamine system (for review see [2-4]) and that we here show that Ex4 suppresses established nicotine-induced effects on the mesolimbic dopamine system [26,27,31], we hypothesize that GLP-1 receptors within these r…”
BackgroundSelf-citationBrubaker, P. L., & Anini, Y. (2003) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y03-107 · Cited by 220 · cited 1×
“response to nutrient ingestion [6] from enteroendocrine L-cells”
BackgroundThe glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents
Egecioglu, E., Steensland, P., Fredriksson, I., Feltmann, K., Engel, J. A., & Jerlhag, E. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.11.009 · Cited by 207 · cited 6×
“This dose of Ex4 was previously determined as the highest dose with no effect per se [18].”
BackgroundResultInfluentialSelf-citationMcMahon, L. R., & Wellman, P. J. (1998) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1998.274.1.r23 · Cited by 199 · cited 2×
“Glucagon-like peptide 1 receptors found in the hypothalamus and NTS have been shown to regulate GLP-1 dependent food intake [15,16] and glucose homeostasis [35], raising the possibility that GLP-1 receptors in these areas also could be of importance for nicotine-induced activation of the mesolimbic dopamine system and…”
BackgroundExpression of the Glucagon‐Like Peptide‐1 Receptor Gene in Rat Brain
Alvarez, E., Roncero, I., Chowen, J. A., Thorens, B., & Blázquez, E. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66030920.x · Cited by 194 · cited 2×
“as the hypothalamus and mesolimbic areas [8-11].”
BackgroundDopamine and alcoholism: neurobiological basis of ethanol abuse
Tupala, E., & Tiihonen, J. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.06.022 · Cited by 191 · cited 1×
“Given that development of nicotine addiction partly depends on the effects of nicotine on the mesolimbic dopamine system (for review see [2-4]) and that we here show that Ex4 suppresses established nicotine-induced effects on the mesolimbic dopamine system [26,27,31], we hypothesize that GLP-1 receptors within these r…”
BackgroundGut Peptide GLP-1 and Its Analogue, Exendin-4, Decrease Alcohol Intake and Reward
Shirazi, R. H., Dickson, S. L., & Skibicka, K. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061965 · Cited by 187
Jerlhag, E. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00125.x · Cited by 184 · cited 1×
“described [20,25].”
Self-citationEgecioglu, E., Engel, J. A., & Jerlhag, E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069010 · Cited by 175 · cited 3×
“Moreover, Ex4 targets reward related parameters such as locomotor stimulation, accumbal dopamine release, CPP and locomotor sensitization not only for nicotine as shown in the present study, but also for alcohol, amphetamine and cocaine as shown elsewhere [18,19,41,42].”
BackgroundResultSelf-citationJerlhag, E., & Engel, J. A. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.01.010 · Cited by 142 · cited 2×
“Previous studies show that the hunger hormones ghrelin and galanin are required for reward induced by nicotine [20,49].”
BackgroundMethodSelf-citationThorens, B., Porret, A., Buhler, L., et al. (1993) · Diabetes · doi:10.2337/diabetes.42.11.1678 · Cited by 126
Identical mRNA for preproglucagon in pancreas and gut
NOVAK, U., WILKS, A., BUELL, G., & McEWEN, S. (1987) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1987.tb11162.x · Cited by 124 · cited 1×
“of the intestinal mucosa [7].”
Engel, J., Fahlke, C., Hulthe, P., H�rd, E., Johannessen, K., Snape, B. M., & Svensson, L. (1988) · Journal of Neural Transmission · doi:10.1007/bf01244784 · Cited by 123 · cited 1×
“Given that development of nicotine addiction partly depends on the effects of nicotine on the mesolimbic dopamine system (for review see [2-4]) and that we here show that Ex4 suppresses established nicotine-induced effects on the mesolimbic dopamine system [26,27,31], we hypothesize that GLP-1 receptors within these r…”
BackgroundSelf-citationGLP-1 analog attenuates cocaine reward
Graham, D. L., Erreger, K., Galli, A., & Stanwood, G. D. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.141 · Cited by 114 · cited 3×
“Moreover, Ex4 targets reward related parameters such as locomotor stimulation, accumbal dopamine release, CPP and locomotor sensitization not only for nicotine as shown in the present study, but also for alcohol, amphetamine and cocaine as shown elsewhere [18,19,41,42].”
BackgroundResultSchirra, J. R. J., Kuwert, P., Wank, U., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1997) · PubMed · Cited by 100
Exendin-4 decreases amphetamine-induced locomotor activity
Erreger, K., Davis, A. R., Poe, A. M., Greig, N. H., Stanwood, G. D., & Galli, A. (2012) · Physiology & Behavior · doi:10.1016/j.physbeh.2012.03.014 · Cited by 95 · cited 2×
“Moreover, Ex4 targets reward related parameters such as locomotor stimulation, accumbal dopamine release, CPP and locomotor sensitization not only for nicotine as shown in the present study, but also for alcohol, amphetamine and cocaine as shown elsewhere [18,19,41,42].”
BackgroundResultOrexin and leptin are associated with nicotine craving: A link between smoking, appetite and reward
von der Goltz, C., Koopmann, A., Dinter, C., Richter, A., Rockenbach, C., Grosshans, M., Nakovics, H., Wiedemann, K., Mann, K. F., Winterer, G., et al. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.09.005 · Cited by 93
Clifford, P. S., Rodriguez, J., Schul, D., Hughes, S., Kniffin, T., Hart, N., Eitan, S., Brunel, L., Fehrentz, J., Martinez, J., et al. (2012) · Addiction Biology · doi:10.1111/j.1369-1600.2011.00339.x · Cited by 80 · cited 1×
“The present sensitization experiment was designed in a similar way as reported by others [28] and investigates expression of nicotine-induced locomotor sensitization.”
MethodGlucagon-like peptide-1 (7–36 amide): a potent glucagonostatic and insulinotropic hormone
Matsuyama, T., Komatsu, R., Namba, M., Watanabe, N., Itoh, H., & Tarui, S. (1988) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(88)80063-9 · Cited by 64 · cited 1×
“Clinically available GLP-1 receptor analogues, such as exenatide and liraglutide, are approved for treatment of type II diabetes since they reduce gastric emptying, glucagon secretion as well as enhance glucose-dependent insulin secretion [43-46].”
BackgroundDifferences in the Central Anorectic Effects of Glucagon-Like Peptide-1 and Exendin-4 in Rats
Barrera, J. G., D'Alessio, D. A., Drucker, D. J., Woods, S. C., & Seeley, R. J. (2009) · Diabetes · doi:10.2337/db09-0281 · Cited by 63 · cited 1×
“Even though Ex4 has been suggested to affect other receptors than the GLP-1 receptor [38-40] the findings that a GLP-1 receptor antagonist blocks the ability of Ex4 to reduce the motivation to consume sucrose [32] supports our hypothesis that the reinforcing properties of rewards such as nicotine are mediated directly…”
BackgroundRegulation of Drug and Palatable Food Overconsumption by Similar Peptide Systems
Morganstern, I., R. Barson, J., & F. Leibowitz, S. (2011) · Current Drug Abuse Reviewse · doi:10.2174/1874473711104030163 · Cited by 49 · cited 3×
“Given that common mechanisms regulate food and drug reward [5] we hypothesize that the GLP-1 signaling system, in addition to homeostatic control of food intake and glucose control, also could be involved in nicotine-induced reward.”
BackgroundResultInfluentialHealth impact of smoking and smoking cessation strategies: current evidence
Duaso, M. J., & Duncan, D. (2012) · British Journal of Community Nursing · doi:10.12968/bjcn.2012.17.8.356 · Cited by 38 · cited 1×
“pulmonary disease and cardiovascular disease [1].”
Malendowicz, L., Nussdorfer, G., Nowak, K., Ziolkowska, A., Tortorella, C., & Trejter, M. (2003) · International Journal of Molecular Medicine · doi:10.3892/ijmm.12.2.237 · Cited by 28 · cited 1×
“Even though Ex4 has been suggested to affect other receptors than the GLP-1 receptor [38-40] the findings that a GLP-1 receptor antagonist blocks the ability of Ex4 to reduce the motivation to consume sucrose [32] supports our hypothesis that the reinforcing properties of rewards such as nicotine are mediated directly…”
BackgroundThe CCK-B antagonist LY288513 blocks the effects of nicotine withdrawal on auditory startle
Rasmussen, K., Czachura, J. F., Kallman, M. J., & Helton, D. R. (1996) · NeuroReport · doi:10.1097/00001756-199604100-00019 · Cited by 26
Mice lacking the galanin gene show decreased sensitivity to nicotine conditioned place preference
Neugebauer, N. M., Henehan, R. M., Hales, C. A., & Picciotto, M. R. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.12.015 · Cited by 21 · cited 1×
“Previous studies show that the hunger hormones ghrelin and galanin are required for reward induced by nicotine [20,49].”
BackgroundCagniard, B., & Murphy, N. P. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.08.021 · Cited by 18
Merchenthaler (1999) · doi:10.1002/(sici)1096-9861(19990111)403:2<261::aid-cne8>3.0.co;2-5
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“425,426 In a murine model of AD, the administration of GLP-1RAs effectively reduced the levels of pathological markers associated with AD.”
BackgroundGLP-1 and weight loss: unraveling the diverse neural circuitry
Kanoski, S. E., Hayes, M. R., & Skibicka, K. P. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00520.2015 · Cited by 290
The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders
Klausen, M. K., Thomsen, M., Wortwein, G., & Fink‐Jensen, A. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15677 · Cited by 259
GLP-1: Molecular mechanisms and outcomes of a complex signaling system
Smith, N. K., Hackett, T. A., Galli, A., & Flynn, C. R. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.04.010 · Cited by 188
Vallöf, D., Maccioni, P., Colombo, G., Mandrapa, M., Jörnulf, J. W., Egecioglu, E., Engel, J. A., & Jerlhag, E. (2016) · Addiction Biology · doi:10.1111/adb.12295 · Cited by 150
Self-citation
Metadata
- Authors
- Egecioglu, E., Engel, J. A., & Jerlhag, E.
- Affiliations
- University of Gothenburg (SE)
- Corresponding author
- Engel, Jörgen A.
- ORCID
- Jerlhag, Elisabet
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-10-18
- Volume
- 8
- Issue
- 10
- Pages
- e77284
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3799694
- OpenAlex
- W2086172137
- Cited by
- 158
- References
- 52
- Citations by year
- 2026: 22 · 2025: 20 · 2024: 15 · 2023: 18 · 2022: 10 · 2021: 18 · 2020: 5 · 2019: 17 · 2018: 6 · 2017: 2 · 2016: 14 · 2015: 6 · 2014: 5
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Vetenskapsrådet (K2010-80X-21496-01-6, 2009-02782, K2006-21X-04247-33-3)
- Sahlgrenska Universitetssjukhuset (148251)
- Systembolaget Aktiebolag
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Keywords
- exendin-4, glucagon-like peptide-1, GLP-1 receptor agonists, nicotine, nicotine dependence, mesolimbic dopamine system, locomotor stimulation, locomotor sensitization, conditioned place preference, reward, nicotine cessation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Conditioning, Psychological, Dopamine, Eating, Limbic System, Male, Motor Activity, Nicotine, Nucleus Accumbens, Peptides, Reward, Tobacco Use Disorder, Venoms, Receptors, Glucagon, Mice, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.